BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

607 related articles for article (PubMed ID: 34023326)

  • 1. Targeting ferroptosis in pancreatic cancer: a double-edged sword.
    Chen X; Kang R; Kroemer G; Tang D
    Trends Cancer; 2021 Oct; 7(10):891-901. PubMed ID: 34023326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ferroptosis: New Strategies and Ideas for the Treatment of Pancreatic Ductal Adenocarcinoma.
    Yang C; Dong Q; Bao H; Ge Y; Xu Z; Li J; Jiang X; Xu Y; Zhong X
    Front Biosci (Landmark Ed); 2024 Jan; 29(1):45. PubMed ID: 38287825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DHA exhibits synergistic therapeutic efficacy with cisplatin to induce ferroptosis in pancreatic ductal adenocarcinoma via modulation of iron metabolism.
    Du J; Wang X; Li Y; Ren X; Zhou Y; Hu W; Zhou C; Jing Q; Yang C; Wang L; Li H; Fang L; Zhou Y; Tong X; Wang Y
    Cell Death Dis; 2021 Jul; 12(7):705. PubMed ID: 34262021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging Potential Mechanism and Therapeutic Target of Ferroptosis in PDAC: A Promising Future.
    Li C; Yin X; Liu Z; Wang J
    Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36499358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MGST1 is a redox-sensitive repressor of ferroptosis in pancreatic cancer cells.
    Kuang F; Liu J; Xie Y; Tang D; Kang R
    Cell Chem Biol; 2021 Jun; 28(6):765-775.e5. PubMed ID: 33539732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ferroptosis-related lncRNA pairs to predict the clinical outcome and molecular characteristics of pancreatic ductal adenocarcinoma.
    Tang R; Wu Z; Rong Z; Xu J; Wang W; Zhang B; Yu X; Shi S
    Brief Bioinform; 2022 Jan; 23(1):. PubMed ID: 34553745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the tumor microenvironment for pancreatic ductal adenocarcinoma therapy.
    Zhang YF; Jiang SH; Hu LP; Huang PQ; Wang X; Li J; Zhang XL; Nie HZ; Zhang ZG
    Chin Clin Oncol; 2019 Apr; 8(2):18. PubMed ID: 31070038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The dark side of ferroptosis in pancreatic cancer.
    Liu J; Dai E; Kang R; Kroemer G; Tang D
    Oncoimmunology; 2021 Jan; 10(1):1868691. PubMed ID: 33489473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Redox Dyshomeostasis with Dual Stimuli-Activatable Dihydroartemisinin Nanoparticles to Potentiate Ferroptotic Therapy of Pancreatic Cancer.
    Wang Y; Chen F; Zhou H; Huang L; Ye J; Liu X; Sheng W; Gao W; Yu H; Wang F
    Small Methods; 2023 May; 7(5):e2200888. PubMed ID: 36446643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Platelet-Vesicles-Encapsulated RSL-3 Enable Anti-Angiogenesis and Induce Ferroptosis to Inhibit Pancreatic Cancer Progress.
    Zhang Y; Huang Z; Cheng J; Pan H; Lin T; Shen X; Chen W; Chen Q; Gu C; Mao Q; Liang Y
    Front Endocrinol (Lausanne); 2022; 13():865655. PubMed ID: 35399954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma.
    Fan JQ; Wang MF; Chen HL; Shang D; Das JK; Song J
    Mol Cancer; 2020 Feb; 19(1):32. PubMed ID: 32061257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Verteporfin induces lipid peroxidation and ferroptosis in pancreatic cancer cells.
    Zhou W; Lim A; Elmadbouh OHM; Edderkaoui M; Osipov A; Mathison AJ; Urrutia R; Liu T; Wang Q; Pandol SJ
    Free Radic Biol Med; 2024 Feb; 212():493-504. PubMed ID: 38184120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Future of immunotherapy in pancreas cancer and the trials, tribulations and successes thus far.
    Wong W; Alouani E; Wei A; Ryu YK; Chabot JA; Manji GA
    Semin Oncol; 2021 Feb; 48(1):57-68. PubMed ID: 33965249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting N-glycosylation of 4F2hc mediated by glycosyltransferase B3GNT3 sensitizes ferroptosis of pancreatic ductal adenocarcinoma.
    Ma H; Chen X; Mo S; Zhang Y; Mao X; Chen J; Liu Y; Tong WM; Lu Z; Yu S; Chen J
    Cell Death Differ; 2023 Aug; 30(8):1988-2004. PubMed ID: 37479744
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Art of War: Ferroptosis and Pancreatic Cancer.
    Liu J; Kang R; Tang D
    Front Pharmacol; 2021; 12():773909. PubMed ID: 34955844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
    Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
    J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current Status of Immunotherapies for Treating Pancreatic Cancer.
    Wu AA; Jaffee E; Lee V
    Curr Oncol Rep; 2019 May; 21(7):60. PubMed ID: 31101991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC).
    Chandana S; Babiker HM; Mahadevan D
    Expert Opin Investig Drugs; 2019 Feb; 28(2):161-177. PubMed ID: 30539678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of Aurora Kinase A Induces Necroptosis in Pancreatic Carcinoma.
    Xie Y; Zhu S; Zhong M; Yang M; Sun X; Liu J; Kroemer G; Lotze M; Zeh HJ; Kang R; Tang D
    Gastroenterology; 2017 Nov; 153(5):1429-1443.e5. PubMed ID: 28764929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ferroptosis and tumor immunity: In perspective of the major cell components in the tumor microenvironment.
    Zhu W; Liu X; Yang L; He Q; Huang D; Tan X
    Eur J Pharmacol; 2023 Dec; 961():176124. PubMed ID: 37925133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.